Evaluating the efficacy and safety of weekly Insulin Icodec vs. Daily Insulin Glargine in type 2 Diabetes Mellitus: a systematic review and meta-analysis
ConclusionOnce-weekly Insulin Icodec demonstrates superior glycemic control with a reduced HbA1c compared to Once-Daily Insulin Glargine U100 while maintaining similar safety profiles. (Source: Journal of Diabetes and Metabolic Disorders)
Source: Journal of Diabetes and Metabolic Disorders - April 23, 2024 Category: Endocrinology Source Type: research
Real-World Effectiveness of the Gla-300 + Cap + App Program in Adult Users Living with Type 2 Diabetes in Taiwan
ConclusionsUse of digital technology within a connected ecosystem such as Gla-300 + Cap + App program could help people with type 2 diabetes to improve their glycemic condition. (Source: Diabetes Therapy)
Source: Diabetes Therapy - April 20, 2024 Category: Endocrinology Source Type: research
Efficacy and safety of basal insulins in people with type 2 diabetes mellitus: a systematic review and network meta-analysis of randomized clinical trials
ConclusionThe efficacy of various basal insulin regimens is comparable. However, they have different safety profiles. IGlar-300 may be the best choice when weight gain is a concern. In contrast, IDeg-100, IDeg-200, IDet, and IGlar-300 may be preferred when hypoglycemia is the primary concern. (Source: Frontiers in Endocrinology)
Source: Frontiers in Endocrinology - March 21, 2024 Category: Endocrinology Source Type: research
Real-World Outcomes of Individualized Targeted Therapy with Insulin Glargine 300 Units/mL in Insulin-Naïve Korean People with Type 2 Diabetes: TOBE Study
ConclusionsThis study showed that initiation of insulin therapy with Gla-300 in people with T2DM using an individualized approach is more effective in achieving an HbA1c target. Moreover, earlier initiation of insulin therapy in people with suboptimally controlled T2DM may increase the success rate of glycemic control.A graphical abstract is available with this article.Graphical Abstract (Source: Advances in Therapy)
Source: Advances in Therapy - March 21, 2024 Category: Drugs & Pharmacology Source Type: research
Efficacy and Safety of Tirzepatide in Patients with Type 2 Diabetes: Analysis of SURPASS-AP-Combo by Different Subgroups
ConclusionsIn this post hoc analysis, tirzepatide was associated with reduced blood glucose and body weight in a predominantly Chinese population with T2D across different subgroups, consistent with previous reports for tirzepatide.Clinical Trial RegistrationNCT04093752. (Source: Diabetes Therapy)
Source: Diabetes Therapy - March 18, 2024 Category: Endocrinology Source Type: research
Evaluation of Glucose Metrics in Adults with Type 1 Diabetes Switching to Insulin Glargine 300 U/mL: A Retrospective, Propensity-Score Matched Study
Diabetes Technology&Therapeutics, Ahead of Print. (Source: Diabetes Technology)
Source: Diabetes Technology - March 6, 2024 Category: Endocrinology Authors: Sara Charleer Steffen Fieuws Christophe De Block Nancy Bolsens Frank Nobels Kristian Mikkelsen Chantal Mathieu Pieter Gillard Source Type: research
IDF23-0185 Efficacy and safety of insulin glargine 300 U/mL in people with T2D in China: subanalysis of the INITIATION study
(Source: Diabetes Research and Clinical Practice)
Source: Diabetes Research and Clinical Practice - March 1, 2024 Category: Endocrinology Authors: L. Chen, B. Wen, H. Liu, H. Wu, B. Duan, H. Shu, Q. Zhang, M. Zhang, M. Li, Y. Han, L. Kang Tags: Other Complications Source Type: research
IDF23-0184 Efficacy and safety of insulin glargine 300 U/mL in people with T2D in China: the INITIATION study
(Source: Diabetes Research and Clinical Practice)
Source: Diabetes Research and Clinical Practice - March 1, 2024 Category: Endocrinology Authors: L. Chen, H. Wan, J. Han, C. Yang, H. Shao, J. Li, W. Yan, M. Zhang, M. Li, Y. Han, L. Kang Tags: Other Complications Source Type: research
IDF23-0379 Switching from reference glargine (Lantus) to biosimilar glargine (Basalog) in T2DM patients, uncontrolled on OAD's
(Source: Diabetes Research and Clinical Practice)
Source: Diabetes Research and Clinical Practice - March 1, 2024 Category: Endocrinology Authors: R. Praveen, B. Saboo, S. Gadve, V. Chopra, S. Reddy, B. Ramanathan, S. Kumar, A. Bhograj, R. Kapur Tags: Diabetes in Crises: Natural Disasters and Conflict Source Type: research
Continuous Glucose Monitoring Profiles and Health Outcomes after Dapagliflozin Plus Saxagliptin vs Insulin Glargine
CONCLUSIONS: DAPA+SAXA and INS were equally effective in reducing HbA1c at 24 weeks, but people with T2D treated with DAPA+SAXA achieved greater time in range, greater reductions in glycemic excursions and variability, less time with hypoglycemia, and improved patient-reported health outcomes.PMID:38412282 | DOI:10.1210/clinem/dgae105 (Source: The Journal of Clinical Endocrinology and Metabolism)
Source: The Journal of Clinical Endocrinology and Metabolism - February 27, 2024 Category: Endocrinology Authors: Donald C Simonson Marcia A Testa Ella Ekholm Maxwell Su Tina Vilsb øll Serge A Jabbour Marcus Lind Source Type: research
Impact of Participant Characteristics on Clinical Outcomes with iGlarLixi in Type 2 Diabetes: Post Hoc Analysis of SPARTA Japan
ConclusionsAchievement of age-defined glycaemic targets with iGlarLixi treatment for 6 months was significantly affected by increased age and body weight loss, regardless of prior insulin exposure.Trial RegistrationUMIN-CTR Trials Registry, UMIN000044126; registered 10 May 2021. (Source: Diabetes Therapy)
Source: Diabetes Therapy - February 16, 2024 Category: Endocrinology Source Type: research
Resolution of insulin resistance, lactic acidosis, and decrease in mechanical support requirements in patients post orthotopic heart transplant with the use of long-acting insulin glargine
This study investigates the efficacy of using a long-acting insulin analog, along with the infusion of regular insulin, in achieving appropriate glycemic control and correcting lactic acidosis in patients post... (Source: Journal of Cardiothoracic Surgery)
Source: Journal of Cardiothoracic Surgery - February 16, 2024 Category: Cardiovascular & Thoracic Surgery Authors: Ribal Darwish, Eva Chen, Steven Minear and Cedric Sheffield Tags: Research Source Type: research
Impact of Participant Characteristics on Clinical Outcomes with iGlarLixi in Type 2 Diabetes: Post Hoc Analysis of SPARTA Japan
ConclusionsAchievement of age-defined glycaemic targets with iGlarLixi treatment for 6 months was significantly affected by increased age and body weight loss, regardless of prior insulin exposure.Trial RegistrationUMIN-CTR Trials Registry, UMIN000044126; registered 10 May 2021. (Source: Diabetes Therapy)
Source: Diabetes Therapy - February 16, 2024 Category: Endocrinology Source Type: research
